MLN 3897

Drug Profile

MLN 3897

Alternative Names: AVE-9897; MLN-3897

Latest Information Update: 18 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals; sanofi-aventis
  • Developer Millennium; sanofi-aventis
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 11 Jul 2008 No development reported - Phase-I for Multiple sclerosis in USA (PO)
  • 14 May 2008 Takeda acquires Millennium
  • 08 Mar 2007 Phase-I clinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top